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Patients with chronic obstructive pulmonary disease 
(COPD) who are not hypoxaemic at rest do not beneﬁt  
from home oxygen
Synopsis
Summary of: Moore RP et al (2011) A randomised trial 
of domiciliary, ambulatory oxygen in patients with COPD 
and dyspnoea but without resting hypoxaemia. Thorax 66: 
32–37. [Prepared by Kylie Hill, CAP Editor.]
Question: In patients with COPD and exertional dyspnoea, 
but without severe hypoxaemia at rest, does domiciliary 
ambulatory oxygen change dyspnoea, health-related quality 
of life, mood, or functional status? Design: Randomised 
controlled trial in which the investigators and participants 
were blinded to group allocation and the randomisation 
sequence was concealed prior to allocation. Setting: In the 
patient’s home with assessments at a tertiary hospital in 
Victoria, Australia. Participants: People with stable COPD 
who: (i) were ex-smokers on optimal medical treatment, (ii) 
had a partial pressure of oxygen in arterial blood > 55mmHg 
at rest, and, (iii) reported moderate to severe functional 
limitation from dyspnoea. Randomisation of 143 patients 
allocated 68 to the cylinder oxygen group and 75 to the 
cylinder air group. Interventions: Participants received 12 
weeks of either cylinder oxygen (intervention) or cylinder 
air (control) set at 6 L/min for use during activities of daily 
living. Both groups were provided with a trolley/stroller to 
transport cylinders as well as verbal and written instruction 
to use the cylinders inside and outside the home during 
activities that caused dyspnoea. Cylinders were identical 
in appearance and weighed 4.2 kg when full. Outcome 
measures: The primary outcome was the dyspnoea domain 
of the Chronic Respiratory Disease Questionnaire (CRDQ). 
Secondary outcomes included dyspnoea measured by the 
Baseline/Transitional Dyspnoea Index, health-related 
quality of life measured by the CRDQ and Assessment of 
Quality of Life Utility Index, mood disturbance measured 
by the Hospital Anxiety and Depression Scale, functional 
exercise capacity measured by the six-minute walk distance, 
and physical activity measured using a pedometer and self-
report. Results: The primary outcome was available for 
139 of the enrolled patients. No between-group differences 
were demonstrated for any outcome. At 12 weeks dyspnoea, 
mean difference 1.1 units (95% CI –0.9 to 3.1), did not 
differ signiﬁcantly between groups. Using domiciliary 
oxygen for participants with exertional desaturation was 
not more predictive of changes in dyspnoea than using air. 
Conclusion: Patients with chronic obstructive pulmonary 
disease (COPD) who are not hypoxaemic at rest do not 
beneﬁt from home oxygen.
[Mean difference and 95% CIs calculated by the CAP 
Editor]
Commentary
Six previous studies that investigated long-term ambulatory 
oxygen therapy (AOT) for patients with COPD demonstrated 
that, on average, AOT did not improve patient outcomes 
(Liker et al 1975, McDonald et al 1995, Eaton et al 2002, 
Lacasse et al 2005, Nonoyama et al 2007, Sandland et 
al 2008). Even after increasing the sample size, Moore 
et al (2010) showed a similar lack of beneﬁt. Is AOT an 
ineffective treatment or have we yet to identify those who 
beneﬁt?
A proportion of patients may ‘respond’ to AOT. However, 
as the consistent deﬁnition of a ‘responder’ has not been 
established, the range of responders within study samples 
is large: 56% in Eaton et al (2002) and 7% in Nonoyama et 
al (2007). Predictors of beneﬁt remain unknown; due partly 
to small sample sizes, but also because psychological and 
behavioural barriers (Earnest 2002) potentially outweigh 
any physiologic beneﬁt of AOT. A low average duration of 
AOT use (ie, < 2 hours/day) is a common ﬁnding.
Until the characteristics of ‘responders’ to AOT are 
established, clinicians should be sceptical of its beneﬁt. 
The best course of action may be to assess on a patient-
by-patient basis using rigorous methods based on N-of-1 
research designs. The cost of such an approach would be 
offset by the savings associated with providing AOT only to 
those who beneﬁt from it and use it.
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